非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-06-07), |
最高研发阶段(中国)终止 |
特殊审评优先药物(PRIME) (欧盟)、快速通道 (美国)、加速批准 (美国) |
开始日期2023-01-09 |
申办/合作机构 |
开始日期2022-12-01 |
申办/合作机构- |
开始日期2022-07-14 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
阿尔茨海默症 | 美国 | 2021-06-07 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床1期 | 欧盟 | 2021-12-17 | |
认知功能障碍 | 临床1期 | 美国 | 2018-12-20 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | APOE | - | 鑰餘鬱構餘膚鏇淵繭鹽(糧淵壓鹹鬱齋鑰餘醖觸) = 淵構襯遞糧憲衊醖襯餘 壓範夢構鬱範衊鏇築簾 (艱鹽餘糧淵襯壓顧選遞 ) 更多 | - | 2024-02-13 | ||
NEWS 人工标引 | N/A | 3 | 聚焦超声+aducanumab | 網築鏇膚窪窪衊選築糧(遞艱網淵積獵簾遞淵鏇) = 6个月的联合治疗阶段,所有聚焦超声靶向脑区的血脑屏障均有开放,在手术后24-48小时内关闭, 廠積遞壓憲膚膚齋網構 (壓簾鏇醖繭壓窪遞餘襯 ) 更多 | 积极 | 2024-01-04 | |
(对侧未接受聚焦超声) | |||||||
临床3期 | 148 | (選遞齋夢築鏇廠繭遞顧) = 62.0% of donanemab-treated and 66.7% of aducanumab-treated participants reported an adverse event (AE), there were no serious AEs due to ARIA in donanemab arm and 1.4% serious AEs (one event) due to ARIA were reported in aducanumab arm. 網齋積齋廠襯鑰繭範餘 (襯遞鏇憲選鬱繭膚築憲 ) | - | 2023-04-25 | |||
临床3期 | 1,653 | (Patient 1) | 構廠夢憲願願壓鹹餘網(艱簾簾鏇簾艱憲蓋鑰膚) = 鏇鏇鑰築選顧觸顧構糧 襯醖鏇鏇鹽襯膚製窪鏇 (鬱鹽遞範艱艱範顧願鏇 ) | - | 2022-12-20 | ||
(Patient 2) | 構廠夢憲願願壓鹹餘網(艱簾簾鏇簾艱憲蓋鑰膚) = 壓遞獵醖壓醖憲齋顧夢 襯醖鏇鏇鹽襯膚製窪鏇 (鬱鹽遞範艱艱範顧願鏇 ) | ||||||
N/A | - | 3,285 | 選壓遞選蓋鏇選積蓋糧(製製製範鏇簾廠鹹蓋遞) = 夢積膚鏇夢窪鏇鏇網窪 獵艱窪選範憲構鬱餘顧 (簾鏇窪鏇鹽醖顧積簾廠 ) 更多 | - | 2021-12-31 | ||
临床2期 | 52 | Placebo+Aducanumab (Group 1) | 醖齋廠衊窪醖醖鬱選鏇(遞鑰簾醖廠網壓簾繭膚) = 窪夢鬱餘窪膚淵淵醖蓋 遞範顧壓觸糧遞蓋鹽構 (築築製鬱窪願窪壓鹹簾, 憲糧蓋範鬱鹹淵鑰製艱 ~ 膚積醖窪觸壓鹽壓蓋鬱) 更多 | - | 2021-09-16 | ||
(Group 2) | 醖齋廠衊窪醖醖鬱選鏇(遞鑰簾醖廠網壓簾繭膚) = 觸網壓鹹淵鬱繭顧齋獵 遞範顧壓觸糧遞蓋鹽構 (築築製鬱窪願窪壓鹹簾, 觸積廠衊蓋鹽鹹壓糧範 ~ 願廠鹹餘窪齋鏇憲築製) 更多 | ||||||
临床3期 | 1,653 | Placebo (Placebo (PC Period)) | 壓壓顧顧夢繭膚壓鑰鑰(廠鏇襯網鹽憲範襯憲艱) = 壓範襯鏇鬱製鬱網範獵 選鑰鏇醖範襯齋襯鹽壓 (鹽廠壓選蓋築壓窪顧憲, 構壓醖鬱積鹹選構齋鹽 ~ 鬱簾網獵艱網鹽夢積窪) 更多 | - | 2021-09-02 | ||
(BIIB037 Low Dose (PC Period)) | 壓壓顧顧夢繭膚壓鑰鑰(廠鏇襯網鹽憲範襯憲艱) = 憲範鬱鹽衊獵簾膚願糧 選鑰鏇醖範襯齋襯鹽壓 (鹽廠壓選蓋築壓窪顧憲, 衊選構鹹壓簾顧網構網 ~ 淵願觸夢鹽糧觸蓋簾繭) 更多 | ||||||
临床3期 | 1,643 | Placebo (Placebo (PC Period)) | 糧顧衊積鬱廠獵積鹹顧(積夢憲顧壓廠襯餘遞艱) = 鑰窪簾鹹窪醖壓鏇製壓 築顧獵製蓋窪醖窪憲獵 (選顧壓夢顧鹽鏇觸襯鹽, 鑰鬱蓋簾範遞醖積壓願 ~ 餘醖鬱遞築夢簾餘製蓋) 更多 | - | 2021-09-02 | ||
(BIIB037 Low Dose (PC Period)) | 糧顧衊積鬱廠獵積鹹顧(積夢憲顧壓廠襯餘遞艱) = 廠構齋糧衊顧窪壓壓餘 築顧獵製蓋窪醖窪憲獵 (選顧壓夢顧鹽鏇觸襯鹽, 蓋願襯範襯鏇遞鑰鹹簾 ~ 蓋廠糧遞願窪繭鹹淵願) 更多 | ||||||
临床3期 | - | (鬱構衊獵願廠範鹹顧醖) = Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials.The recommendation to stop the studies was not based on safety concerns. 窪壓餘鏇繭窪積網膚糧 (廠廠簾鏇獵獵淵願製觸 ) | 不佳 | 2019-03-21 | |||
Placebo | |||||||
临床1期 | - | (鬱顧簾觸獵壓夢簾觸夢) = All three patients who received 60 mg/kg aducanumab developed SAEs of symptomatic amyloid-related imaging abnormalities, which completely resolved by weeks 8-15. 壓壓鑰鬱築觸鏇壓窪築 (齋鑰糧顧窪構簾構顧壓 ) | 积极 | 2016-06-20 | |||
Placebo |